Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn

Women’s Health, Prostate Cancer Assets To Get A Boost

 
• By Mandy Jackson
  
Big fish eats smaller fish
Sumitomo subsidiary Sumitovant is buying the remaining shares of Myovant • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business